Compare · GNLX vs NVO
GNLX vs NVO
Side-by-side comparison of Genelux Corporation (GNLX) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GNLX and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $223.88B, about 1715.7x GNLX ($130.5M).
- Over the past year, GNLX is down 5.8% and NVO is down 24.6% - GNLX leads by 18.8 points.
- NVO has been more active in the news (5 items in the past 4 weeks vs 4 for GNLX).
- NVO has more recent analyst coverage (25 ratings vs 6 for GNLX).
- Company
- Genelux Corporation
- Novo Nordisk A/S
- Price
- $2.91+0.34%
- $50.54+2.97%
- Market cap
- $130.5M
- $223.88B
- 1M return
- -1.36%
- +15.18%
- 1Y return
- -5.83%
- -24.65%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2023
- News (4w)
- 4
- 5
- Recent ratings
- 6
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest GNLX
- Attovia Therapeutics Appoints John W. Smither to Board of Directors
- Director Smither John W sold $34,898 worth of shares (12,000 units at $2.91), decreasing direct ownership by 12% to 91,403 units (SEC Form 4)
- Genelux Announces Publication of Translational Analysis Supporting Immune Activation and Chemotherapy Sensitization with Olvi‑Vec in Ovarian Cancer
- SEC Form 8-K filed by Genelux Corporation
- President and CEO Zindrick Thomas was granted 730,601 shares, increasing direct ownership by 137% to 1,263,913 units (SEC Form 4)
- General Counsel Groen Eric was granted 233,957 shares (SEC Form 4)
- Director Thomas John was granted 28,409 shares, increasing direct ownership by 6% to 501,193 units (SEC Form 4)
- Chief Financial Officer Pulisic Matthew was granted 278,906 shares (SEC Form 4)
- Director Tyree James L was granted 28,409 shares, increasing direct ownership by 42% to 96,483 units (SEC Form 4)
- Chief Technical Officer Cappello Joseph was granted 174,841 shares, increasing direct ownership by 113% to 329,390 units (SEC Form 4)
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S